Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection (Q61774378)

From Wikidata

Jump to navigation Jump to search

scientific article published on 28 December 2011

Language	Label	Description	Also known as
English	Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection	scientific article published on 28 December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

molecular medicine

0 references

cutaneous leishmaniasis

1 reference

based on heuristic

inferred from title

Leishmania donovani

object named as

Leishmania donovani

1 reference

based on heuristic

inferred from title

Craig W. Roberts

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

S A Campbell

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

J Alawa

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

B Doro

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

F L Henriquez

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A Nok

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

C B I Alawa

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

M Alsaadi

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

A B Mullen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

K C Carter

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

language of work or name

0 references

publication date

28 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1357-1363

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Human immunodeficiency virus and leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Leishmaniasis Vaccine: Where are We Today?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Multiple sequence alignment with the Clustal series of programs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

CD28 and IL-4: two heavyweights controlling the balance between immunity and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

BALB/c mice deficient in CD4 T cell IL-4Rα expression control Leishmania mexicana Load although female but not male mice develop a healer phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Immune effector mechanism in parasitic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Progressive disease or protective immunity to Leishmania major infection: the result of a network of stimulatory and inhibitory interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Leishmania mexicanaandLeishmania major:Attenuation of Wild‐Type Parasites and Vaccination with the Attenuated Lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

DNA vaccines: designing strategies against parasitic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.12.067

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.12.067

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22210224%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61774378&oldid=2221849849"